SK bioscience and Sanofi extend partnership to develop next-gen vaccines

SK bioscience and Sanofi, a global healthcare company, extended their partnership to co-develop next-generation pneumococcal conjugate vaccines (PCVs) for both pediatric and adult populations, the bio company said on Monday.

2024-12-23

Beyfortus RSV shot to launch in Korea next month

Beyfortus, a long-acting RSV antibody treatment for infants, will launch in Korea next month, aiming to address rising hospitalization rates linked to the virus, especially among children under two years old.

2024-12-03

SK, Sanofi complete phase II trial for pneumococcal vaccine

SK bioscience and Sanofi completed the Phase II clinical trial for a pneumococcal vaccine that the companies are jointly developing, the Korean pharmaceutical company said Friday.

2023-06-30

[INTERVIEW] ABL Bio has grown from go-getter to go-to company

For ABL Bio CEO Lee Sang-hoon, this year’s BIO International Convention (BIO USA) is totally different from what it used to be three years ago.

2022-06-20

Sanofi pulls out of Hanmi diabetes drug trials, ends contract

Paris-based Sanofi has decided to drop ongoing Phase 3 clinical trials and marketing rights of Hanmi Pharmaceutical’s efpeglenatide, a diabetes drug.

2020-09-09

Sanofi seeking to walk away from huge deal with Hanmi

Paris-based Sanofi is seeking an exit from a deal with Hanmi Pharmaceutical involving global marketing rights to efpeglenatide, a diabetes drug. Shares of Kospi-listed Hanmi fell almost 10 percent on the news.

2020-05-14